Human Epidermal Growth Factor Receptor-2 Expression in Ductal Invasive Carcinoma Mammae in Correlation With Patients’ Age and Tumor Differensiation
EXPRESSION OF HER2 BIOMARKER ON CARCINOMA MAMMAE
Abstract
Introduction: Breast cancer (BC) is a term that refers to a group of diseases in which the cells of the breast change and grow uncontrollably. While the majority of breast cancer risk factors are within human control, the illness can migrate when cancer cells enter the blood or lymphatic circulation and then expand to other regions of the body. Additionally, breast cancer is a diverse disease at the cellular level; The activation of the human epidermal growth factor receptor 2 (HER2), activation of hormone receptors, and/or BRCA mutations are all molecular characteristics.
Purpose: This study intends to evaluate the association of patient profiles to HER2 expression and the role of HER2 in predicting the degree of differentiation of breast cancer.
Method: This study is a descriptive analytic study that enrolled 178 patients with invasive ductal breast cancer in Makassar. Data collection contains anamnesis of patient’s demographic information, clinical history, any supportive investigations performed, and the findings of immunohistochemistry testing, then analyzed using the Fisher exact test.
Results: There was a significant association between tumour differentiation and HER2 expression in breast cancer patients as evaluated by immunohistochemistry (p=0.011). Additionally, no association was identified between age and HER2 expression (p=0.057).
Conclusion: These results suggest that the more advanced the tumours, the more biomarkers are generated. On the other hand, age has no effect on the development of cancer.
Downloads
References
2. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Vol. 5, Nature Reviews Disease Primers. 2019. 1–5 p.
3. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis [Internet]. 2018;5(2):77–106. Available from: https://doi.org/10.1016/j.gendis.2018.05.001
4. American Cancer Society. What is breast cancer ? [Internet]. American Cancer Society. Cancer Facts and Figures Atlanta, Ga: American Cancer Society. 2017. p. 1–19. Available from: http://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html
5. Aryana S, Suka Aryana I, At Adiputra P, Prayudi PK, Permatasari Y, Setiawan HP, et al. OAJ Gerontol & Geriatric Med Histology and Biologic Characteristics of Breast Cancer in Elderly of Balinese Population. OAJ Gerontol Geriatr Med [Internet]. 2018;3(5):1–6. Available from: https://www.researchgate.net/publication/324982706
6. Watkins EJ. Overview of breast cancer. J Am Acad Physician Assist. 2019;32(10):13–7.
7. Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8(1):23–31.
8. Veta M, Pluim JPW, Van Diest PJ, Viergever MA. Breast cancer histopathology image analysis: A review. IEEE Trans Biomed Eng. 2014;61(5):1400–11.
9. Kundale J, Dhage S. Classification of Breast Cancer using Histology images: Handcrafted and Pre-Trained Features Based Approach. IOP Conf Ser Mater Sci Eng. 2021;1074(1):1–2.
10. Arau´jo T, Aresta G, Castro E, Rouco J, Aguiar P, Eloy C, et al. Classification of Breast Cancer Based on Histology Images Using Convolutional Neural Networks. PLoS One. 2017;6(1):1–3.
11. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):1–23.
12. Guler EN. Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer. Eur J Breast Heal. 2017;13(4):168–74.
13. Mitri Z, Constantine T, O’Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012;2012(April):1–7.
14. Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. BMC Clin Pathol. 2019;19(1):1–6.
15. Hicks DG, Kulkarni S. HER2+ breast cancer: Review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129(2):263–73.
16. Jaclyn A. Freudenberg, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol. 2009;87(1):1–11.
17. Vranić S, Bešlija S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J Basic Med Sci. 2021;21(1):1–4.
18. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA - J Am Med Assoc. 2019;321(3):288–300.
19. Hosonaga M, Arima Y, Sampetrean O, Komura D, Koya I, Sasaki T, et al. HER2 heterogeneity is associated with poor survival in HER2-positive breast cancer. Int J Mol Sci. 2018;19(8):1–12.
20. Abdalla O J, Jens H, Fathi B A. HER2/Neu Distribution in Female Breast Cancer in Libya: Correlation with Clinicopathological Features and Survival. Int J Cancer Clin Res. 2021;8(2):1–8.
21. World Health Organization. Globocan world cancer report. The Global Cancer Observatory. 2020. p. 1–2.
22. Aravind S, Muttath G, Bincy F, Murugesan M, Nayanar SK, Balasubramanian S. Breast cancer in young women of age 35 years and below: Initial experience at a tertiary cancer centre in south india. Onkol i Radioter. 2021;15(8):1–6.
23. Clarke CA, Keegan THM, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst. 2012;104(14):1094–101.
24. Tagliabue G, Fabiano S, Contiero P, Barigelletti G, Castelli M, Mazzoleni G, et al. Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data. J Clin Med. 2021;10(24):1–2.
25. Chumsri S, Serie DJ, Li Z, Pogue-geile KL, Soyano- AE, Mashadi-hossein A, et al. Effects of Age and Immune Landscape on Outcome in HER2- positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clin Cancer Res. 2019;25(14):4422–30.
26. Eiriz IF, Vaz Batista M, Cruz Tomás T, Neves MT, Guerra-Pereira N, Braga S. Breast cancer in very young women—a multicenter 10-year experience. ESMO Open [Internet]. 2021;6(1):100029. Available from: https://doi.org/10.1016/j.esmoop.2020.100029
This work is licensed under a Creative Commons Attribution 4.0 International License.
